Julia L. Glade Bender, MD
Julia Glade Bender, MD cares for children, adolescents, and young adults with solid tumors, particularly neuroblastoma, sarcoma, germ cell tumors, and other rare tumors. She has special expertise in the treatment of young patients with cancers that have become resistant (refractory) to treatment or have relapsed (come back) after therapy.
Dr. Bender is attracted to the intellectual and emotional challenges of diagnosing, understanding, and treating complex illnesses. There's much to be learned about tumor biology and the growth pathways involved in cancer that can be translated into better therapies for children. Her goal is to apply the results of her clinical experience and research to improve the care of young people with cancer, using more effective therapies with fewer side effects. For most patients, standard chemotherapy using existing anticancer drugs will continue to be the best approach. But for others, there's great hope that the newer biologic and targeted therapies being developed today may have activity against childhood cancers. Dr. Bender is also intrigued by genetics and the new sequencing technologies that allow for the exploration of the differences between tumor cells and normal cells in an individual child with cancer.
At NewYork-Presbyterian/Morgan Stanley Children's Hospital, Dr. Bender serves as medical director for the Precision in Pediatrics Sequencing (PIPseq) Program, which works to identify the molecular drivers of each patient's cancer and use this information to personalize his or her treatment using novel, biologically targeted investigational agents. She also directs the Developmental Therapeutics Program, which explores the safety and effectiveness of new cancer therapies in children with refractory disease through clinical trials. The center is the only pediatric oncology program in New York selected to participate in the Children's Oncology Group (COG) Phase I Consortium, a group of 21 institutions in the country designated by the National Cancer Institute to conduct Phase I pediatric clinical trials - the earliest phase of studies for patients. The Developmental Therapeutics Program also serves as a home for industry-sponsored and investigator-initiated trials supported by data generated by laboratory research partners. For patients with refractory or relapsed cancer who are not participating in clinical trials, Dr. Bender and her team work to assemble a combination of existing drugs that is customized to each patient's disease.
My mission is to improve cure rates for the most aggressive pediatric tumors and mitigate side effects one patient at a time. Early phase clinical trials not only help to move the field forward but also provide children access to the newest investigational agents in development to treat cancer including inhibitors of growth pathways, modulators of cellular and molecular control mechanisms and immunotherapy. I established the Pediatric Developmental Therapeutics Program to serve as the research home for studies sponsored by the Children’s Oncology Group (COG) Phase 1 Consortium, other consortia specific to recurrent neuroblastoma and leukemia, industry and investigator-initiated trials. I have also provided scientific leadership for over 15 early phase clinical trials sponsored by the National Cancer Institute and pharmaceutical industry and have developed an international reputation for the early pediatric development of the vascular endothelial growth factor (VEGF) neutralizing agents, bevacizumab and aflibercept, and several multi-tyrosine kinase inhibitors including sorafenib, sunitinib, and pazopanib. My ability to effectively participate in team clinical research has led to appointments to numerous prominent COG committees, including the Developmental Therapeutics, Bone Tumor, and Neuroblastoma Steering committees where I have served as the leader of the task force on post-consolidation “maintenance” therapies and new agents liaison. On a broader scale, I serve as consultant to the Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration (FDA) and am a member of the NCI Pediatric and Adolescent Solid Tumor Steering Committee.
Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A, Stegmaier K, Roberts CW, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 Jan 28. doi: 10.1001/jamaoncol.2015.5689. [Epub ahead of print].
Tannenbaum-Dvir S, Glade-Bender JL, Church AJ, Janeway KA, Harris MH, Mansukhani MM, Nagy PL, Andrews SJ, Murty VV, Kadenhe-Chiweshe A, Connolly EP, Kung AL, Dela Cruz FS. Characterization of a novel fusion gene 1 EML4-NTRK3 in an aggressive case of congenital fibrosarcoma. Cold Spring Harbor Molecular Case Studies. 2015: a000471.
Oberg JA, Glade Bender J, Cohn EG, Morris MC, Ruiz J, Chung WK, Applebaum PS, Kung AL, Levine JM. Overcoming Challenges to Meaningful Informed Consent for Whole Genome Sequencing in Pediatric Cancer Research. Pediatric Blood and Cancer, Pediatr Blood Cancer. 2015 Aug;62(8):1374-80. [Epub 2015 Apr 1; PMID:25832998].
Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, Leary SE, Nelson MD, Adamson PC, Blaney SM, Weigel B. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: A report from the children's oncology group phase I consortium. Pediatr Blood Cancer. Pediatr Blood Cancer. 2015 Jan;62(1):45-51. [Epub 2014 Sep 24; PMID:25257751].
Glade Bender J, Lee A, Reid JM, Baruchel S, Roberts T, Voss S, Wu B, Ahern C, Ingle AM, Harris P, Weigel B, Blaney SM. A Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children with Refractory Solid Tumors including Soft Tissue Sarcoma: A Children’s Oncology Group Phase I Consortium Report. J Clin Oncol. 2013 Aug 20;31(24):3034-3043. [Epub 2013 Jul 15; PMID: 23857966].
Glade Bender J, Blaney SM, Borinstein SC, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, Park JR. A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children’s Oncology Group Phase I Consortium Report. Clin Cancer Res. 2012 Sep 15;18(18):5081-9. [PMID: 22791883].
Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008 Jan 20; 26(3):399-405[PMID: 18202416].